68Ga-AAZTA-NI-093 PET/CT: First-in-human Study

Recruiting now · Early Phase 1

Conditions studied: Prostate Cancer (Adenocarcinoma)

In brief

68Ga-AAZTA-093 is a novel radiotracer incorporating a hypoxia sensitive nitroimidazole(NI)-moiety and a PSMA-targeting. In this study, we observed the safety, biodistribution, radiation dosimetry and diagnostic value of 68Ga-AAZTA-NI-093 PET/CT in patients with prostate cancer.

Key facts

Study ID

NCT06612580

Run by

First Affiliated Hospital of Fujian Medical University

People needed

10

Starts

2024-09-01

Expected to finish

2025-12-31

Last updated by the study team

2024-09-25

Who can join

Age: 18 and older, up to 80. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• confirmed treated or untreated prostate cancer patients;
• signed written consent.

You may not qualify if…

• known allergy against PSMA;
• any medical condition that in the opinion of the investigator may significantly interfere with study compliance.

Where it is running

• The First Affiliated Hospital of Fujian Medical University — Fuzhou, Fujian, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.